This article is more than 5 years old. Information may no longer be current.
Enthesitis, dactylitis associated with greater burden of disease in psoriatic arthritis
Click Here to Manage Email Alerts
Enthesitis and dactylitis were associated with a greater burden of disease in patients with psoriatic arthritis, according to data published from the Corrona registry.
Philip J. Mease, MD, of the Swedish Medical Center and University of Washington School of Medicine, and colleagues assessed patient characteristics, disease activity and patient-reported outcomes in 1,567 patients with psoriatic arthritis — 420 with enthesitis and 228 with dactylitis — who were enrolled in the Corrona Psoriatic Arthritis and Spondyloarthrtitis (PsA/SpA) registry. Researchers evaluated association of dactylitis and enthesitis with minimal disease activity, health assessment questionnaire scores, patient-reported pain and fatigue and work productivity, with adjustment for age, sex, race BMI, disease duration and history of prescription drug use.
Researchers found that patients with dactylitis or enthesitis had greater disease activity and had reduced odds to be in minimal disease activity. In addition, patients with enthesitis had worse functional status, increased patient-reported pain and fatigue and higher likelihood of any work impairment (adjusted OR = 1.57), overall work impairment (adjusted OR = 1.85) and activity impairment (adjusted OR = 1.77). Dactylitis had similar associations that were not significant.
“Identification, assessment and then effective management of enthesitis and dactylitis are important steps in lowering the overall burden of PsA,” the researchers wrote. – by Will Offit
Disclosure: Novartis provided financial support for the study. Mease reports receiving research grants and consulting fees from, and serving on the speakers’ bureau of AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Pfizer and UCB; research grants and consulting fees from Lilly and Novartis; consultant fees from and serving on the speakers’ bureaus of Crescendo, Genentech and Janssen; and consultant fees from Corrona and Merck. Please see the full study for a list of all other researchers’ relevant financial disclosures.
Click Here to Manage Email Alerts